Matthew A. Powell

10.1k total citations · 2 hit papers
182 papers, 5.7k citations indexed

About

Matthew A. Powell is a scholar working on Obstetrics and Gynecology, Reproductive Medicine and Oncology. According to data from OpenAlex, Matthew A. Powell has authored 182 papers receiving a total of 5.7k indexed citations (citations by other indexed papers that have themselves been cited), including 95 papers in Obstetrics and Gynecology, 76 papers in Reproductive Medicine and 45 papers in Oncology. Recurrent topics in Matthew A. Powell's work include Endometrial and Cervical Cancer Treatments (91 papers), Ovarian cancer diagnosis and treatment (69 papers) and Cervical Cancer and HPV Research (22 papers). Matthew A. Powell is often cited by papers focused on Endometrial and Cervical Cancer Treatments (91 papers), Ovarian cancer diagnosis and treatment (69 papers) and Cervical Cancer and HPV Research (22 papers). Matthew A. Powell collaborates with scholars based in United States, Canada and Netherlands. Matthew A. Powell's co-authors include David G. Mutch, Paul J. Goodfellow, Janet S. Rader, Feng Gao, Premal H. Thaker, Israel Zighelboim, Randall K. Gibb, Jason D. Wright, David E. Cohn and Pamela M. Pollock and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Matthew A. Powell

175 papers receiving 5.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers

2006 482 citations Matthew A. Powell et al. profile →
Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer

2019 289 citations David G. Mutch, Paul DiSilvestro et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Matthew A. Powell United States	40	3.3k	2.4k	1.3k	1.1k	942	182	5.7k
Naveena Singh United Kingdom	37	1.8k 0.6×	2.1k 0.9×	703 0.6×	1.5k 1.3×	1.2k 1.3×	144	5.2k
Franco Odicino Italy	33	4.0k 1.2×	3.5k 1.4×	1.0k 0.8×	1.3k 1.1×	1.4k 1.5×	128	6.7k
Jan J. Jobsen Netherlands	35	4.3k 1.3×	3.1k 1.3×	508 0.4×	1.1k 1.0×	922 1.0×	92	6.4k
Oluwole Fadare United States	36	1.5k 0.5×	1.4k 0.6×	1.3k 1.0×	953 0.8×	543 0.6×	255	4.7k
Carmen Tornos United States	38	1.9k 0.6×	2.0k 0.8×	950 0.8×	916 0.8×	578 0.6×	91	4.4k
Yoshiki Mikami Japan	41	1.8k 0.6×	1.4k 0.6×	737 0.6×	921 0.8×	1.2k 1.3×	231	5.3k
Vicky Makker United States	34	2.0k 0.6×	1.5k 0.6×	975 0.8×	1.9k 1.7×	435 0.5×	180	4.6k
Jeffrey D. Seidman United States	42	2.2k 0.7×	3.9k 1.6×	862 0.7×	725 0.6×	389 0.4×	105	5.5k
Russell Vang United States	52	2.1k 0.6×	4.1k 1.7×	1.5k 1.2×	1.9k 1.6×	589 0.6×	169	7.9k
Jacob Rotmensch United States	33	2.4k 0.7×	1.6k 0.6×	752 0.6×	796 0.7×	533 0.6×	132	4.5k

Countries citing papers authored by Matthew A. Powell

Since Specialization

Citations

This map shows the geographic impact of Matthew A. Powell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew A. Powell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew A. Powell more than expected).

Fields of papers citing papers by Matthew A. Powell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew A. Powell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew A. Powell. The network helps show where Matthew A. Powell may publish in the future.

Co-authorship network of co-authors of Matthew A. Powell

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew A. Powell. A scholar is included among the top collaborators of Matthew A. Powell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew A. Powell. Matthew A. Powell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Valentine, Mark C., Mary M. Mullen, Matthew A. Powell, et al.. (2025). Multiomic Characterization of Pre- and Post-Neoadjuvant Chemotherapy–Treated Ovarian Cancer Reveals Mediators of Tumorigenesis and Chemotherapy Response. Cancer Research. 85(18). 3558–3570. 1 indexed citations

Mutch, David G., Athina Voulgari, Xian Chen, et al.. (2024). Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti–PD‐L1, for BRCA wild‐type, platinum‐sensitive, recurrent ovarian cancer. Cancer. 130(11). 1940–1951. 2 indexed citations

Jørgensen, Trine Lembrecht, Destin Black, David Cibula, et al.. (2024). Time course of adverse events in primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN-6-NSGO/GOG-3031/RUBY trial.. Journal of Clinical Oncology. 42(16_suppl). 5607–5607. 1 indexed citations

Erickson, Britt, Danielle Enserro, Heather A. Lankes, et al.. (2024). Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk or pertuzumab, trastuzumab, and hyaluronidase-zzxf in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma (NRG-GY026).. Journal of Clinical Oncology. 42(16_suppl). TPS5641–TPS5641. 4 indexed citations

Powell, Matthew A. & Marcus Vetter. (2024). Endometrial Cancer: Updates in Molecular Characterization and Treatment Opportunities. SHILAP Revista de lepidopterología.

Chase, Dana M., Line Bjørge, Robert L. Coleman, et al.. (2023). #267 Quality-adjusted time without symptoms of disease or toxicity in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel in the ENGOT-EN6/GOG-3031/RUBY trial. A8–A9. 2 indexed citations

Mullen, Mary M., Nicholas C. Spies, Tiandao Li, et al.. (2023). Genetic characterization of primary and metastatic high-grade serous ovarian cancer tumors reveals distinct features associated with survival. Communications Biology. 6(1). 688–688. 18 indexed citations

Powell, Matthew A. & Shuya Wei. (2022). Surface Characterization and Optimization of Porous Zinc Anodes to Improve Cycle Stability by Mitigating Dendritic Growth. Journal of The Electrochemical Society. 169(10). 100511–100511. 5 indexed citations

Powell, Matthew A., et al.. (2022). The Use of Targeted Agents in the Treatment of Gynecologic Cancers. Current Treatment Options in Oncology. 23(1). 15–28. 3 indexed citations

10.

Rao, Bin, Yifeng Zeng, Ruimin Chen, et al.. (2019). Optical Resolution Photoacoustic Microscopy of Ovary and Fallopian Tube. Scientific Reports. 9(1). 14306–14306. 23 indexed citations

11.

Liu, Jingxia, Rachel G. Tabak, Katherine C. Fuh, et al.. (2019). Low rates of cascade genetic testing among families with hereditary gynecologic cancer: An opportunity to improve cancer prevention. Gynecologic Oncology. 156(1). 140–146. 31 indexed citations

12.

Guo, Lei, Peinan Zhao, Ian S. Hagemann, et al.. (2018). Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer. Molecular Cancer Therapeutics. 18(2). 389–398. 38 indexed citations

13.

Ko, Emily, Laura J. Havrilesky, Ronald D. Alvarez, et al.. (2018). Society of Gynecologic Oncology Future of Physician Payment Reform Task Force report: The Endometrial Cancer Alternative Payment Model (ECAP). Gynecologic Oncology. 149(2). 232–240. 9 indexed citations

14.

Jeske, Y., Shamshad Ali, Sara A. Byron, et al.. (2017). FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology. 145(2). 366–373. 41 indexed citations

15.

Rao, Yuan James, Caressa Hui, Anupama Chundury, et al.. (2017). Which patients with inoperable vulvar cancer may benefit from brachytherapy in addition to external beam radiation? A Surveillance, Epidemiology, and End Results analysis. Brachytherapy. 16(4). 831–840. 8 indexed citations

16.

Byron, Sara A., Michael G. Gartside, Candice L. Wellens, et al.. (2008). Inhibition of Activated Fibroblast Growth Factor Receptor 2 in Endometrial Cancer Cells Induces Cell Death Despite PTEN Abrogation. Cancer Research. 68(17). 6902–6907. 119 indexed citations

17.

Gius, David, Eric Y. Chuang, Sheng Feng, et al.. (2007). Profiling Microdissected Epithelium and Stroma to Model Genomic Signatures for Cervical Carcinogenesis Accommodating for Covariates. Cancer Research. 67(15). 7113–7123. 76 indexed citations

18.

Zighelboim, Israel, Paul J. Goodfellow, Amy P. Schmidt, et al.. (2007). Differential Methylation Hybridization Array of Endometrial Cancers Reveals Two Novel Cancer-Specific Methylation Markers. Clinical Cancer Research. 13(10). 2882–2889. 33 indexed citations

19.

Gartside, Michael G., Sara A. Byron, Candice L. Wellens, et al.. (2007). Inhibition of FGFR2 in endometrial cancer cells induced apoptosis despite constitutive activation of the PI3K/AKT pathway.. Molecular Cancer Therapeutics. 6. 1 indexed citations

20.

Buttin, Barbara M., Matthew A. Powell, Paul J. Goodfellow, et al.. (2006). Increased risk for abnormalities on perioperative colon screening in patients with microsatellite instability–positive endometrial carcinoma. International Journal of Gynecological Cancer. 16(6). 1980–1986. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact